The average take from a bank robbery is a bit over $4,000. Les Funtleyder , a Health Care Strategist at Miller Tabak and the author of Healthcare Investing: Profiting from the New World of Pharma, Biotech, and Health Care Services, says that even though pharma theft will likely "not be a material problem" for Lilly (on which he has a Neutral rating) and other drug companies, it must continue to take steps to ensure the security of its supply chains. "The knock on effect of pharmaceutical theft is that people could start to feel concerned about where their drugs are coming from," Funtleyder notes. "Supply chain integrity is incredibly important in the US. you need to be able to trust your drugs are what they are, that they're coming from where they're supposed to be coming from, and that they're in the condition they need to be in.". 
Share:  The average take from a bank robbery is a bit over $4,000.<span class="sent"> <span class="analyst">Les Funtleyder</span> , a Health Care Strategist at Miller Tabak and the author of Healthcare Investing: Profiting from the New World of Pharma, Biotech, and Health Care Services, says that even though pharma theft will likely "not be a material problem" for <span class="company">Lilly</span> (on which he has a Neutral rating) and other drug companies, it must continue to take steps to ensure the security of its supply chains.</span> "The knock on effect of pharmaceutical theft is that people could start to feel concerned about where their drugs are coming from," Funtleyder notes. "Supply chain integrity is incredibly important in the US. you need to be able to trust your drugs are what they are, that they're coming from where they're supposed to be coming from, and that they're in the condition they need to be in.". Tweet this 

Erbitux, the colon cancer treatment made by Indianapolis based Lilly, can cost $40,000, said Les Funtleyder , a Miller Tabak & Co. LLC analyst in New York, in an e mail today. 
Share:  <span class="sent">Erbitux, the colon cancer treatment made by Indianapolis based <span class="company">Lilly</span>, can cost $40,000, said <span class="analyst">Les Funtleyder</span> , a Miller Tabak & Co. LLC analyst in New York, in an e mail today.</span> Tweet this 

Now, Merck owns Schering after a $41 billion purchase in November. Another pressure may soon be lifted from Merck. Whichever way the health care debate ends, it will be a relief for the pharmaceutical industry as a whole, said Les Funtleyder, an analyst for Miller Tabak. Certainty is better for the whole industry than uncertainty, he added. 
Share:  Now, Merck owns <span class="company">Schering</span> after a $41 billion purchase in November. Another pressure may soon be lifted from Merck.<span class="sent"> Whichever way the health care debate ends, it will be a relief for the pharmaceutical industry as a whole, said <span class="analyst">Les Funtleyder</span>, an analyst for Miller Tabak.</span> Certainty is better for the whole industry than uncertainty, he added. Tweet this 

The rumor mill has cranked up again, according to analyst firm Miller Tabak, citing recent chatter in the blogosphere. While Miller Tabak analyst Alex Henderson acknowledges that H P needs to compete with Cisco, he said that the tech giant is an "extremely price sensitive buyer" and is unlikely to make a move for F5. Cisco's decision to move into the server space with the launch of its last year certainly agitated H P, its long time server partner. 
Share:  The rumor mill has cranked up again, according to analyst firm Miller Tabak, citing recent chatter in the blogosphere.<span class="sent"> While Miller Tabak analyst <span class="analyst">Alex Henderson</span> acknowledges that H P needs to compete with Cisco, he said that the tech giant is an "extremely price sensitive buyer" and is unlikely to make a move for <span class="company">F5</span>. Cisco's decision to move into the server space with the launch of its last year certainly agitated H P, its long time server partner.</span> Tweet this 

The rumor mill has cranked up again, according to analyst firm Miller Tabak, citing recent chatter in the blogosphere. While Miller Tabak analyst Alex Henderson acknowledges that H P needs to compete with Cisco, he said that the tech giant is an "extremely price sensitive buyer" and is unlikely to make a move for F5. Cisco's decision to move into the server space with the launch of its last year certainly agitated H P, its long time server partner. 
Share:  The rumor mill has cranked up again, according to analyst firm Miller Tabak, citing recent chatter in the blogosphere.<span class="sent"> While Miller Tabak analyst <span class="analyst">Alex Henderson</span> acknowledges that H P needs to compete with <span class="company">Cisco</span>, he said that the tech giant is an "extremely price sensitive buyer" and is unlikely to make a move for F5. <span class="company">Cisco</span>'s decision to move into the server space with the launch of its last year certainly agitated H P, its long time server partner.</span> Tweet this 

The rumor mill has cranked up again, according to analyst firm Miller Tabak, citing recent chatter in the blogosphere. While Miller Tabak analyst Alex Henderson acknowledges that H P needs to compete with Cisco, he said that the tech giant is an "extremely price sensitive buyer" and is unlikely to make a move for F5. Cisco's decision to move into the server space with the launch of its last year certainly agitated H P, its long time server partner. 
Share:  The rumor mill has cranked up again, according to analyst firm Miller Tabak, citing recent chatter in the blogosphere.<span class="sent"> While Miller Tabak analyst <span class="analyst">Alex Henderson</span> acknowledges that <span class="company">H P</span> needs to compete with Cisco, he said that the tech giant is an "extremely price sensitive buyer" and is unlikely to make a move for F5. Cisco's decision to move into the server space with the launch of its last year certainly agitated <span class="company">H P</span>, its long time server partner.</span> Tweet this 

Risperdal global sales peaked at $4.5 billion in 2007, declining after the company lost patent protection, company filings showed."We don't view it as a problem for J&J at this moment," said Les Funtleyder , an analyst with Miller Tabak & Co in New York, who recommends buying J&J shares and doesn't own any. "The one exception, and we haven't really seen this, is when there's a sort of systemic problem. somebody at the top says, ‘You shall market off label no matter what the law says.'". Four J&J competitors that also make atypical antipsychotics paid a total of more than $2.5 billion to resolve government claims they marketed medicines for off label uses. 
Share:  Risperdal global sales peaked at $4.5 billion in 2007, declining after the company lost patent protection, company filings showed."We<span class="sent"> don't view it as a problem for <span class="company">J&J</span> at this moment," said <span class="analyst">Les Funtleyder</span> , an analyst with Miller Tabak & Co in New York, who recommends buying <span class="company">J&J</span> shares and doesn't own any.</span> "The one exception, and we haven't really seen this, is when there's a sort of systemic problem. somebody at the top says, ‘You shall market off label no matter what the law says.'". Four <span class="company">J&J</span> competitors that also make atypical antipsychotics paid a total of more than $2.5 billion to resolve government claims they marketed medicines for off label uses. Tweet this 

The joint venture is expected to generate at least $5.3 billion in annual revenues that will be unaffected by patent expirations or the complexity of government reimbursements. "This achieves one of our main objectives, which is to achieve more sustainable growth,'' said Christopher Viehbacher, chief executive officer of Sanofi Aventis. Viehbacher said the joint venture would help reduce the overall risk for both drug makers by helping to move the business away from its traditional dependence on "the cyclical boom bust of small molecule blockbuster'' prescription medicines. Industry analysts agreed. "(Animal health) is a good business that isn't open to some of the same vicissitudes that you get from traditional pharma,'' said Les Funtleyder, an analyst with Miller Tabak in New York City. 
Share:  The joint venture is expected to generate at least $5.3 billion in annual revenues that will be unaffected by patent expirations or the complexity of government reimbursements. "This achieves one of our main objectives, which is to achieve more sustainable growth,'' said Christopher Viehbacher, chief executive officer of <span class="company">Sanofi Aventis</span>. Viehbacher said the joint venture would help reduce the overall risk for both drug makers by helping to move the business away from its traditional dependence on "the cyclical boom bust of small molecule blockbuster'' prescription medicines. Industry analysts agreed.<span class="sent"> "(Animal health) is a good business that isn't open to some of the same vicissitudes that you get from traditional pharma,'' said <span class="analyst">Les Funtleyder</span>, an analyst with Miller Tabak in New York City.</span> Tweet this 

Miller Tabak downgrades Riverbed Technology (Nasdaq: RVBD ) from Buy to Hold. 
Share:  <span class="sent"><span class="analyst">Miller Tabak</span> downgrades <span class="company">Riverbed Technology</span> (Nasdaq: RVBD ) from Buy to Hold.</span> Tweet this